ArticleCancers2021
Lipid Level, Lipid Variability, and Risk of Multiple Myeloma: A Nationwide Population-Based Study of 3,527,776 Subjects.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Genetic evidence reveals phosphatidylcholine as a mediator in the causal relationship between omega-3 and multiple myeloma risk.Scientific reports · 2025Pooled it
- Lipid levels and multiple myeloma risk: insights from Meta-analysis and mendelian randomization.Lipids in health and disease · 2024Pooled it
- Plasma metabolomic signatures of all and cause-specific cancers: a multi-platform population-based study.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Serum lipid levels and risk of lymphoid malignancies in the UK Biobank study.British journal of cancer · 2025Article
- The instrumental role of lipids in governing the sensitivity of multiple myeloma to ferroptosis.Discover oncology · 2025Review
- Lipids, apolipoproteins, carbohydrates, and risk of hematological malignancies.European journal of epidemiology · 2025Article
- Cholesterol metabolism reprogramming in multiple myeloma: examining its specificity and impact on the immune microenvironment.American journal of cancer research · 2025Review
- Protective Effects of High-Density Lipoprotein on Cancer Risk: Focus on Multiple Myeloma.Biomedicines · 2024Review
- High-density lipoprotein cholesterol and multiple myeloma: A systematic review and meta-analysis.Atherosclerosis plus · 2023Article
- Low cholesterol levels are associated with increasing risk of plasma cell neoplasm: A UK biobank cohort study.Cancer medicine · 2023Article
- Article
- Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis.Frontiers in endocrinology · 2023Article
- Association between Cholesterol Level and the Risk of Hematologic Malignancy According to Menopausal Status: A Korean Nationwide Cohort Study.Biomedicines · 2022Article
- Association of Metabolic Parameter Variability with Esophageal Cancer Risk: A Nationwide Population-Based Study.Journal of personalized medicine · 2022Article
- Modulation of Cellular Redox Parameters for Improving Therapeutic Responses in Multiple Myeloma.Antioxidants (Basel, Switzerland) · 2022Review
- Serum Abnormal Metabolites for Evaluating Therapeutic Response and Prognosis of Patients With Multiple Myeloma.Frontiers in oncology · 2022Article
- Article
- Associations of Variability in Metabolic Parameters with Lung Cancer: A Nationwide Population-Based Study.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Background: There is evidence that abnormality in lipid metabolism promotes cancer development. This study investigated whether lipid level and its variability are associated with the development of MM at a population level. (2) Methods: A retrospective cohort study included a total of 3,527,776 subjects aged 40 and above who participated in ≥3 health examinations within the previous five years, including the index year (2012-2013). Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) were measured, and visit-to-visit lipid variability were calculated by variability independent of the mean (VIM) method. The study population was followed from the health examination date in the index year until the diagnosis of MM, death, or the last follow-up date (31 December 2017). (3) Results: During a median (5-95%) 5.1 years of follow-up, 969 subjects developed MM. A lower risk of MM was observed with higher quartiles of baseline lipid levels compared to the lowest quartile group (Q4 vs. Q1: adjusted hazard ratios (aHRs) 0.51, 95% confidence interval (CI) (0.42-0.61) for TC; 0.50 (0.41-0.61) for HDL-C; 0.65 (0.54-0.77) for LDL-C; and 0.72 (0.60-0.87) for TG in model (3). Among all lipid measures, only variability in HDL-C was associated with risk of MM: aHRs (95% CI) were 1.12 (0.91-1.38), 1.19 (0.97-1.46), and 1.34 (1.09-1.65) in the Q2, Q3, and Q4, respectively, compared to the Q1 of VIM of HDL-C. (4) Conclusions: This study shows that patients with lower lipid levels and high HDL-C variability are at increased risk of developing MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.